Why Australian Pharmaceutical Industries Ltd shares are falling on its half-year results

Credit: Priceline

Investors have reacted to disappointing results for the half-year to February 28 2018 for health and beauty services company Australian Pharmaceutical Industries Ltd (ASX: API), with its share price down 2% to $1.47 at the time of writing.

Australian Pharmaceutical Industries reported a drop in statutory NPAT of 14.4% to $24.9 million, with revenue flat at $2 billion and dividends maintained at 3.5c per share fully-franked.

Share prices for Australian Pharmaceutical have been volatile in the past 12 months, trending down from $2.03 at this time last year.

The company blames “suppressed retail conditions” for the drop in earnings, and similar conditions have affected others in the sector, with peer Mayne Pharma Group Ltd (ASX: MYX) reporting a 17% decrease in revenue, 82% drop in reported EBITDA and a net loss after tax of $174.2 million for the six months to December 31, 2018.

Elsewhere in the healthcare sector Ramsay Health Care Limited Fully Paid Ord. Shrs (ASX: RHC) shares could be in buy territory as Ramsay ploughs ahead on its global expansion strategy.

Healthscope Ltd (ASX: ASX: HSO) is also one to watch with its pathology services business going great guns.

The Disruptors: 3 Revolutionary Aussie Companies to Back for 2018

We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.

That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Cochlear or REA Group.

We’ve found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!

Motley Fool contributor Carin Pickworth has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.